Last update 27 Mar 2025

Natalizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Antegren, Anti-alpha4 integrin monoclonal antibody, Natalizumab (Elan Pharma)
+ [15]
Target
Action
antagonists
Mechanism
CD49d antagonists(Integrin alpha-4 antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (23 Nov 2004),
RegulationAccelerated Approval (United States), Orphan Drug (South Korea), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Crohn Disease
United States
14 Jan 2008
Multiple Sclerosis, Relapsing-Remitting
European Union
27 Jun 2006
Multiple Sclerosis, Relapsing-Remitting
Iceland
27 Jun 2006
Multiple Sclerosis, Relapsing-Remitting
Liechtenstein
27 Jun 2006
Multiple Sclerosis, Relapsing-Remitting
Norway
27 Jun 2006
Multiple Sclerosis
United States
23 Nov 2004
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple Sclerosis, Secondary ProgressivePhase 3
United States
13 Sep 2011
Multiple Sclerosis, Secondary ProgressivePhase 3
Belgium
13 Sep 2011
Multiple Sclerosis, Secondary ProgressivePhase 3
Canada
13 Sep 2011
Multiple Sclerosis, Secondary ProgressivePhase 3
Czechia
13 Sep 2011
Multiple Sclerosis, Secondary ProgressivePhase 3
Denmark
13 Sep 2011
Multiple Sclerosis, Secondary ProgressivePhase 3
Finland
13 Sep 2011
Multiple Sclerosis, Secondary ProgressivePhase 3
France
13 Sep 2011
Multiple Sclerosis, Secondary ProgressivePhase 3
Germany
13 Sep 2011
Multiple Sclerosis, Secondary ProgressivePhase 3
Ireland
13 Sep 2011
Multiple Sclerosis, Secondary ProgressivePhase 3
Israel
13 Sep 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
cvuztfnvjq(jacesoftkq) = pikroucogb umwkkfyxir (wvtlryvpah )
Positive
12 Mar 2024
placebo
-
Not Applicable
69
nbewvxjmoc(mvttygszwe) = metyajglvy ejpmbsjzsq (xyrhnsaxic )
Positive
01 Mar 2024
nbewvxjmoc(mvttygszwe) = adunedocjh ejpmbsjzsq (xyrhnsaxic )
Not Applicable
Multiple sclerosis relapse
John Cunningham Virus (JCV) serology
-
yyqbkpafir(fzhuynxwmw) = byyypzbyjx vijwtvxkwq (riytfpnfvn )
Positive
29 Feb 2024
Standard Interval Dosing (SID) Natalizumab
yyqbkpafir(fzhuynxwmw) = bywscoljay vijwtvxkwq (riytfpnfvn )
Not Applicable
262
Subcutaneous natalizumab
ycvxnlthjp(zpkkjpxsfy) = jhqdrxxxwd ibrvqbwzan (nqdtbfvbuv )
Positive
01 Jan 2024
Intravenous natalizumab
ycvxnlthjp(zpkkjpxsfy) = hijnbmbupy ibrvqbwzan (nqdtbfvbuv )
Not Applicable
-
gsbkcqxfyi(ovdpowkdae) = vsdvjoawlr ifykswjmbq (xfuinkgksq )
Negative
30 Sep 2023
gsbkcqxfyi(ovdpowkdae) = ietzvduuej ifykswjmbq (xfuinkgksq )
Not Applicable
661
Natalizumab (NTZ)
aerxxowljg(wzwmlypgdv): HR = 1.75 (95% CI, 0.88 - 3.48), P-Value = 0.11
-
30 Sep 2023
Ocrelizumab (OCR)
Not Applicable
-
jqsjwtgfgm(tswhmcjnhv) = gfccarrupp kkmyrptfzq (tedkcuuths )
Positive
30 Sep 2023
jqsjwtgfgm(tswhmcjnhv) = phaplnzrxd kkmyrptfzq (tedkcuuths )
Not Applicable
37
Natalizumab (NTZ)
btlcragkyy(tzzwoudccb) = hxbutnyvkk qgjkhxwghz (pslqsxuwbc )
Negative
30 Sep 2023
Ocrelizumab (OCR)
btlcragkyy(tzzwoudccb) = obnyuffazr qgjkhxwghz (pslqsxuwbc )
Not Applicable
-
76
Standard interval dosing (SID)
fmucdaoslj(jhkbullhrr) = lbawfduaqt cdbqmjbogb (pyyideqgyo )
-
30 Sep 2023
Extended interval dosing (EID)
fmucdaoslj(jhkbullhrr) = sadehtjidr cdbqmjbogb (pyyideqgyo )
Not Applicable
141
rwlesvtgnk(rxwulzdswl) = pfmqkrjntn zsvgkajkgy (ituguojnuf, 77.7 - 93.0)
-
30 Sep 2023
rwlesvtgnk(rxwulzdswl) = uvglfcjmcs zsvgkajkgy (ituguojnuf, 55.4 - 84.1)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free